BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Otsuka Pharmaceutical Co., Ltd. 

2-9 Kanda Tsukasa-cho
Chiyoda-ku
Tokyo    101-8535  Japan
Phone: 03-3292-0021 Fax:


SEARCH JOBS


Industry
Pharmaceutical






 Company News
Otsuka Pharmaceutical Co., Ltd. Acquires Rights To Hematological Cancer Treatment Dacogen® From Eisai Inc. (ESALF.PK) (U.S.) 3/31/2014 8:21:36 AM    More...
IBM Corporation (IBM) And Otsuka Pharmaceutical Co., Ltd. Develop Transformative Care Coordination Solution 3/26/2014 10:09:14 AM    More...
Otsuka Pharmaceutical Co., Ltd.'s Samsca® Approved In Japan As The World's First Drug Therapy For ADPKD, A Rare Kidney Disease 3/24/2014 8:53:20 AM    More...
Otsuka SA And The Union Announce Global TB Research & Innovation Award 3/19/2014 10:09:42 AM    More...
H. Lundbeck A/S (LUN.CO) And Otsuka Pharmaceutical Co., Ltd. Initiate European Launch Of Abilify Maintena® (Aripiprazole), A Once-Monthly Formulation For The Treatment Of Schizophrenia 3/17/2014 9:02:15 AM    More...
The Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S (LUN.CO) Alliance Announces Once-Monthly (Pr)ABILIFY MAINTENA(™) (ARIPIPRAZOLE For Prolonged Release Injectable Suspension)1 Now Approved In Canada For The Maintenance Treatment Of Schizophrenia In Stabilized Adult Patients 2/13/2014 7:13:21 AM    More...
Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S (LUN.CO) To Present New Data On Brexpiprazole In Major Depression (MDD) At European Congress Of Psychiatry (EPA) 1/24/2014 9:26:43 AM    More...
Otsuka Pharmaceutical Co., Ltd. And Lundbeck Inc. (LUN.CO) To Present New Data On Brexpiprazole In Major Depressive Disorder (MDD) At European Psychiatry Association 2014 Congress 1/24/2014 6:52:59 AM    More...
Lundbeck Inc. (LUN.CO) And Otsuka Pharmaceutical Co., Ltd. To Co-Develop A Vaccine, Lu AF20513, Their Third Collaborative Development Project To Tackle Alzheimer’s Disease 12/11/2013 7:37:32 AM    More...
CHMP Recommends Otsuka Pharmaceutical Co., Ltd.'s Deltyba™ (Delamanid) For EU Approval For Treatment Of Multidrug-Resistant Tuberculosis (MDR-TB) In Combination With Optimized Background Regimen (OBR) 11/25/2013 8:09:36 AM    More...
12345678910...

//-->